Utility of the Cylex Assay in Cardiac Transplant Recipients

Journal of Heart and Lung Transplantation

Volumn 27, Issue 8, 2008, Pages 817-822

  Gupta, Sachin ^a   Mitchell, Joshua D ^b   Markham, David W ^a   Mammen, Pradeep P A ^a   Patel, Parag C ^a   Kaiser, Patricia A ^a   Stastny, Peter ^b   Ring, W Steves ^b   DiMaio, J Michael ^b   Drazner, Mark H ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZATHIOPRINE; BASILIXIMAB; COTRIMOXAZOLE; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADULT; AGED; ARTICLE; CARDIAC GRAFT REJECTION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; FEMALE; FOLLOW UP; GRAFT INFECTION; GRAFT RECIPIENT; HEART FAILURE; HEART TRANSPLANTATION; HERPES ZOSTER; HUMAN; IMMUNOASSAY; INFECTION RISK; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PNEUMOCYSTOSIS; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT RESPONSE;

ADULT; AFRICAN AMERICANS; AGED; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOASSAY; IMMUNOSUPPRESSION; LEUKOCYTE COUNT; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 47649103385     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2008.05.014     Document Type: Article

References (9)

1. Kowalski R., Post D., Schneider M.C., et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 17 (2003) 77-88
2. Sottong P.R., Rosebrock J.A., Britz J.A., and Kramer T.R. Measurement of T-lymphocyte responses in whole-blood cultures using newly synthesized DNA and ATP. Clin Diagn Lab Immunol 7 (2000) 307-311
3. Kowalski R.J., Post D.R., Mannon R.B., et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 82 (2006) 663-668
4. Preiksaitis J.K., Brennan D.C., Fishman J., and Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 5 (2005) 218-227
5. Rosenberg P.B., Vriesendorp A.E., Drazner M.H., et al. Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. J Heart Lung Transplant 24 (2005) 1327-1331
6. - heart transplant recipients shortly after completion of 3 months of valganciclovir prophylaxis. J Heart Lung Transplant 27 (2008) 536-539
7. Eisen H., and Ross H. Optimizing the immunosuppressive regimen in heart transplantation. J Heart Lung Transplant 23 suppl (2004) S207-S213
8. Knight R.J., Kerman R.H., McKissick E., et al. A pilot study of immunosuppression minimization after pancreas-kidney transplantation utilizing thymoglobulin induction and sirolimus maintenance therapy. Transplant Proc 37 (2005) 3538-3541
9. Zeevi A., Britz J.A., Bentlejewski C.A., et al. Monitoring immune function during tacrolimus tapering in small bowel transplant recipients. Transplant Immunol 15 (2005) 17-24